Literature DB >> 3728007

A comparative study of the mouth to caecum transit time in children and adults using a weight adapted lactulose dose.

G Vreugdenhil, M Sinaasappel, J Bouquet.   

Abstract

Mouth to caecum transit time (M.C.T.T.) was assessed in 41 subjects divided into 3 age groups (0-1 year, 1-4 years and 22-27 years) with the hydrogen breath test (H.B.T.) using lactulose as the hydrogen source (250 mg/kg; minimal dose 1.5 g in a 10% aqueous solution). The M.C.T.T. remained constant from the second month of age. In children under 1 year of age a high percentage of non-responders was found compared to the older age-groups. In 8 adults two test-substrates, pure lactulose (Legendal, L) and a mixture of lactulose, lactose and galactose (Duphalac, D) were compared. There was no significant difference in M.C.T.T., mean hydrogen production and clinical symptoms using D or L as substrate. We conclude that the H.B.T. using a relative dosage is a suitable test for children, but under the age of 1 year it is less useful because of the high percentage of non-responders. Because of the relation between body height and small bowel length the results suggest an increase in the velocity of the intestinal content with age.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3728007     DOI: 10.1111/j.1651-2227.1986.tb10234.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  3 in total

1.  Orocaecal transit time in patients with Crohn disease.

Authors:  H Götze; A Ptok
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

Review 2.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

3.  Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Authors:  Stefan Willmann; Corina Becker; Rolf Burghaus; Katrin Coboeken; Andrea Edginton; Jörg Lippert; Hans-Ulrich Siegmund; Kirstin Thelen; Wolfgang Mück
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.